DOCSLIB.ORG

Lorenzo P. Moja MD, Msc, Dr Pub Health, Phd

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Lorenzo P. Moja MD, Msc, Dr Pub Health, Phd Curriculum Vitae Lorenzo P. Moja MD, MSc, Dr Pub Health, PhD November 2017 Offices Department of Biomedical Sciences for Policy, Access and Use (PAU) Health, University of Milan Essential Medicines and Health Products Dipartimento di Scienze Biomediche per la Department (EMP) Salute World Health Organization Università degli Studi di Milano 20, avenue Appia Via Carlo Pascal, 36 1211 Geneva 20133 Milano Switzerland Tel: +390250315097 Tel: +41227913756 E-mail: [email protected] E-mail: [email protected] Clinical Epidemiology Unit, IRCCS Orthopaedic Institute Galeazzi Unità di Epidemiologia Clinica IRCCS Istituto Ortopedico Galeazzi Via Riccardo Galeazzi, 4 20161 Milano E-mail: [email protected] Actual Professional Appointments 2015 Technical Officer, Policy, Access and Use (PAU), Essential Medicines and Health Products Department (EMP), Headquarter World Health Organization 2011 Assistant Professor (on leave), Department of Biomedical Sciences for Health, University of Milan, Milan 2012 Head, Clinical Epidemiology Unit (on leave), IRCCS Orthopedic Institute Galeazzi, Milan 1 Biography In 2000 Dr Moja (b. Milan, 1974) obtained his medical degree from University of Milan (Italy). After medical school he completed a Master Program in Systematic Reviews and Evidence Syntheses. He spent a training period as Research Fellow at the Epidemiology Program in Ottawa (Canada), where the Editorial Base of the Cochrane Effective Practice and Organisation of Care (EPOC) review group was based. During his stay (2003-2004) Dr. Moja was trained in epidemiology, knowledge transfer and health services research with special reference to the methodology of systematic reviews and clinical trials. In 2004 he completed the medical specialty of Hygiene, Preventive and Community Medicine from the University of Milan. In 2014 he gained a Doctorate (D Phil) from Open University (UK), researching into strategies for success of competency-based Continuous Medical Education (CME) programs for medical doctors. In 2005 Dr Moja joined the staff of the Cochrane Collaboration. He was the Deputy-Director of the Italian Cochrane Centre in Milan from 2007 to 2011. He has been scientist and research manager for various projects at the Mario Negri for Pharmaceutical Research (2005-2011) focusing on drug evaluations, from animal studies to phase IV trials. Since 2011 he has been Assistant Professor of Public Health at the University of Milan. In 2012 he started the Clinical Epidemiology Unit at the Galeazzi Orthopedic Institute, a research unit to improve the quality of scientific studies in physical therapy and beyond. In 2015 Dr Moja joined the Department of Essential Medicines and Health Products of the World Health Organization (WHO). He serves as technical officer at the Secretariat of the Model List of Essential Medicines (EML), a global standard to guide countries in identifying medicines that should be not only widely available in national health care systems, but also affordable to individuals and the community. It is used by all UN organizations and by more than 150 countries, where it forms the basis for coverage-program formularies and national EMLs. Dr Moja is a member of various steering groups and advisory committees related to research & innovation. Among the others he participated in the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) Group and is actively involved in the GRADE Working Group. He is a member of the WHO Guideline Review Committee, reviewing guideline development. He was part of the UniMiVal (2012-2015), a group of young researchers supporting the evaluation board of Milan University in assessing the quality of all PhD courses, with the goal of improving postgraduate education, and of the executive board of the Associazione Alessandro Liberati – Italian Cochrane Network (2012-2015). Dr Moja is a senior clinical editor of Internal and Emergency Medicine, the official journal of the Italian Society of Internal Medicine (in the period 2008-2013 he was Deputy Editor). He is Editor of the Dr Cochrane, an innovative online Continuing Professional Education Development product that embeds evidence from Cochrane reviews into a vignette based narrative. He is editor of several CME courses for medical doctors. Dr Moja is a member of the PhD program in Epidemiology, Environment and Public Health at the University of Milan. He managed several academic activities, including unit’s finances and grants, overseeing academic and administrative operations for postgraduate courses. Dr Moja has published over 100 peer reviewed papers and editorials, book chapters and commentaries. One fifth of his scientific articles were published in top-ranked medical journals (Annals of Internal Medicine, BMJ, Cochrane, JAMA, PLOS Medicine). He authored several reviews on biotechnology medicines that offered the basis of reimbursement decisions at national health 2 systems. He has been commissioned the development of innovative strategies to better support health policy makers around the world in making evidence-informed decisions. His scientific works have been cited thousands of times. Dr Moja is the recipient of several national and international grants. He is one of the very few Italian researchers receiving two young investigator awards (2009 and 2012) from the Minister of Health. Research and Health-System Interests Dr. Moja worked in the fields of evidence-based medicine, clinical investigation, experimental and observational epidemiology, research methodology, health systems research, and innovative models to promote the quality and efficiency of clinical decisions. His research is concentrated in a few themes. Dr Moja has an interest in solving questions that clinicians face in their practice synthetizing evidence. He developed systematic reviews and meta-analyses of medical interventions across several medical specialties - autoimmune diseases, cardiology, neurology, oncology, orthopaedics, palliative medicine, paediatrics, physiotherapy, surgery, and rare diseases. He is author of several Cochrane, non-Cochrane reviews and clinical guidelines focused on both efficacy and safety of therapies, including innovative biotech medicines. His reviews on trastuzumab for breast cancer and bevacizumab for macular degeneration served as basis for coverage decisions in several countries. A second area of work relates to methodology. He has undertaken research on: a) the design, conduct and analysis of experimental studies in animals and humans; b) the risk of bias and validity of primary studies and systematic reviews; c) the transparent and accurate reporting of research; and d) how to handle scientific disputes across experts and guideline panels, using consensual methods such as the GRADE. Dr Moja has experience in the area of knowledge transfer adopting new media technologies (i.e. e- learning, point-of-care information services and computer decision support systems) and communication strategies (i.e. different format of evidence). He conducted studies to explore the effectiveness of different knowledge transfer intervention for doctors, specialists and patients. He had evaluated a wide range of point-of-care services (e.g. Clinical Evidence, UpToDate, ACP Pier, eTG and Dynamed) for their editorial and evidence-based quality. He is the principal investigator of two large randomized controlled trials to assess the impact of computer decision support systems in general and specialty hospitals. The fourth focus is on health and research policies to ensure optimal payback from public and private investments. He studies how governments, international agencies like the WHO and donors (research foundations), evaluate complex portfolio of innovations and health care programs and determine whether the right mix of highly-effective medicines and services get to those who need them, at an acceptable cost. The research supports health system policymakers and stakeholders around the world in taking advantage of the best available research evidence, including studies other than randomized controlled trials. Context, institutional constraints, interest group pressures, values and other factors that drive the policymaking process are analysed to set agendas, take well- considered actions and communicate the rationale for actions effectively. 3 Education background and qualifications May 2014 DPhil – Open University, UK Affiliated Research Centre Programme: Mario Negri Institute for Pharmacological Research, Milan Topic: E-learning Programs Based in High Quality Evidence to Transfer Knowledge and to Improve Practice for Health Care Professionals Supervisors: Prof. Alessandro Liberati, Dr. Jeremy Grimshaw Support: Mario Negri Institute for Pharmacological Research November 2011 Post-graduate courses in “Statistics applied to clinical questions”, School of Medicine, University of Modena and Reggio Emilia, Modena Supervisor: Prof. Roberto D’Amico November 2004 Specialty in Hygiene, Preventive and Community Medicine (duration 4 years), Medical School, University of Milan, Milan Thesis: Strutture di diagnosi e ricovero alternative per pazienti con ictus cerebrale acuto: valutazione delle opportunità di un’analisi costi-efficacia e costi-utilità affiancate al trial clinico PROSIT [Alternative strategies for stroke care in Italy: exploring cost- effectiveness and cost-utility analyses from a prospective, observational study (PROSIT)] Supervisor thesis: Prof. Vittorio Mapelli, Prof.ssa Livia Candelise Supervisor medical activities: Prof. Francesco Auxilia
Load more

Recommended publications
  • Academia and Clinic
    Academia and Clinic Annals of Internal Medicine Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement David Moher, PhD; Alessandro Liberati, MD, DrPH; Jennifer Tetzlaff, BSc; Douglas G. Altman, DSc; and the PRISMA Group* Editor’s Note: In order to encourage dissemination of the article, we summarize a revision of these guidelines, re- PRISMA Statement, this article is freely accessible on the An- named PRISMA (Preferred Reporting Items for Systematic nals of Internal Medicine Web site (www.annals.org) and reviews and Meta-Analyses), which have been updated to will be also published in PLOS Medicine, BMJ, Journal of address several conceptual and practical advances in the Clinical Epidemiology, and Open Medicine. The authors science of systematic reviews (Box 1). jointly hold the copyright of this article. For details on further use, see the PRISMA Web site (www.prisma-statement.org). TERMINOLOGY ystematic reviews and meta-analyses have become in- The terminology used to describe a systematic review Screasingly important in health care. Clinicians read and meta-analysis has evolved over time. One reason for them to keep up to date with their field (1, 2), and they are changing the name from QUOROM to PRISMA was the often used as a starting point for developing clinical prac- desire to encompass both systematic reviews and meta- tice guidelines. Granting agencies may require a systematic analyses. We have adopted the definitions used by the Co- review to ensure there is justification for further research chrane Collaboration (9). A systematic review is a review of (3), and some health care journals are moving in this di- a clearly formulated question that uses systematic and ex- rection (4).
    [Show full text]
  • A Review of Online Evidence-Based Practice Point-Of-Care Information Summary Providers
    JOURNAL OF MEDICAL INTERNET RESEARCH Banzi et al Original Paper A Review of Online Evidence-based Practice Point-of-Care Information Summary Providers Rita Banzi1; Alessandro Liberati1,2; Ivan Moschetti1; Ludovica Tagliabue1,3; Lorenzo Moja1 1Italian Cochrane Centre, Mario Negri Institute for Pharmacological Research, Milan, Italy 2University of Modena and Reggio Emilia, Modena, Italy 3University of Milan, Milan, Italy Corresponding Author: Rita Banzi Italian Cochrane Centre Mario Negri Institute for Pharmacological Research Via La Masa 19 Milan, 20159 Italy Phone: 390 239014671 Fax: 390 23559048 Email: [email protected] Related Articles: Comment in:Alper BS. Review of Online Evidence-based Practice Point-of-Care Information Summary Providers: Response by the Publisher of DynaMed. J Med Internet Res. 2010 Sep 09;12(3) p. e39 http://www.jmir.org/2010/3/e39/ Comment in:Banzi R, Liberati A, Moschetti I, Tagliabue L, Moja L. Review of Online Evidence-based Practice Point-of-Care Information Summary Providers: Authors' Reply to the Response by the Publisher of DynaMed. J Med Internet Res. 2010 Sep 09;12(3) p. e40 http://www.jmir.org/2010/3/e40/ Abstract Background: Busy clinicians need easy access to evidence-based information to inform their clinical practice. Publishers and organizations have designed specific tools to meet doctors' needs at the point of care. Objective: The aim of this study was to describe online point-of-care summaries and evaluate their breadth, content development, and editorial policy against their claims of being ªevidence-based.º Methods: We searched Medline, Google, librarian association websites, and information conference proceedings from January to December 2008.
    [Show full text]
  • An Updated Guideline for Reporting Systematic Reviews
    This is a repository copy of The PRISMA 2020 statement : An updated guideline for reporting systematic reviews. White Rose Research Online URL for this paper: https://eprints.whiterose.ac.uk/173287/ Version: Published Version Article: Page, Matthew J, McKenzie, Joanne E, Bossuyt, Patrick M et al. (23 more authors) (2021) The PRISMA 2020 statement : An updated guideline for reporting systematic reviews. Journal of Clinical Epidemiology. ISSN 0895-4356 https://doi.org/10.1016/j.jclinepi.2021.03.001 Reuse This article is distributed under the terms of the Creative Commons Attribution (CC BY) licence. This licence allows you to distribute, remix, tweak, and build upon the work, even commercially, as long as you credit the authors for the original work. More information and the full terms of the licence here: https://creativecommons.org/licenses/ Takedown If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [email protected] including the URL of the record and the reason for the withdrawal request. [email protected] https://eprints.whiterose.ac.uk/ ARTICLE IN PRESS JID: JCE [mNS; March 17, 2021;19:26 ] Journal of Clinical Epidemiology xxx (xxxx) xxx ORIGINAL ARTICLE The PRISMA 2020 statement: An updated guideline for reporting systematic reviews a , ∗ a b c Matthew J. Page , Joanne E. McKenzie , Patrick M. Bossuyt , Isabelle Boutron , d e f, g h Tammy C. Hoffmann , Cynthia D. Mulrow , Larissa Shamseer , Jennifer M. Tetzlaff , i ,j a k l m, n , o Elie A. Akl , Sue E. Brennan , Roger Chou , Julie Glanville , Jeremy M.
    [Show full text]
  • Annual Report 1995 to 1996 and Strategic Plan
    The Nordic Cochrane Centre and Network Report 1995-1996 and Strategic plan for 1997 ADDRESS: The Nordic Cochrane Centre Rigshospitalet, Dept. 5222 Blegdamsvej 9 DK-2100 Copenhagen Ø Denmark Tel: +45 35 45 55 71 Fax: +45 35 45 65 28 Email: [email protected] 25 November 1996 CONTENTS SUMMARY 1 THE COCHRANE COLLABORATION 2 Background 2 Aims and principles 2 Collaboration 3 Organization 3 Collaborative review groups 3 Handsearchers 3 Fields 3 Cochrane Centres 4 Methods working groups 4 Steering Group 4 Financial support 5 The Cochrane Library 5 Derivative publications 6 THE NORDIC COCHRANE CENTRE AND NETWORK 6 Aims 6 Current staff at the Nordic Cochrane Centre 7 Nordic Cochrane Network 7 Advisory Board 8 Sources of funding support 8 ACTIVITIES 1995-1996 8 Third annual Cochrane Colloquium 9 Handsearching of randomised trials 9 Review groups 9 Methods working groups 10 Cochrane Workshops 10 Courses on systematic reviews 10 Exploratory and other meetings for review groups 11 Advisory Board meetings 11 Software development 11 Dissemination 11 References 12 Acknowledgements 12 STRATEGIC PLAN FOR 1997 13 Principal objectives 13 Targets 14 APPENDIX 1. Relevant publications 1995-1996 16 APPENDIX 2. Meetings and courses addressed 1995-1996 19 APPENDIX 3. Visitors received at the Centre since 1993 21 1 SUMMARY Reports of original medical research are far too numerous and dispersed to be of practical value to clinicians and other decision makers in health care. Reviews of research thus occupy a key position in the chain which links research with clinical practice. However, because scientific principles have not generally guided reviews of research evidence, useless and even harmful forms of health care have not been distinguished efficiently from useful forms of care.
    [Show full text]
  • Preferred Reporting Items for Systematic
    Moher et al. Systematic Reviews 2015, 4:1 http://www.systematicreviewsjournal.com/content/4/1/1 RESEARCH Open Access Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement David Moher1*, Larissa Shamseer1, Mike Clarke2, Davina Ghersi3, Alessandro Liberatiˆ, Mark Petticrew4, Paul Shekelle5, Lesley A Stewart6 and PRISMA-P Group Abstract Systematic reviews should build on a protocol that describes the rationale, hypothesis, and planned methods of the review; few reviews report whether a protocol exists. Detailed, well-described protocols can facilitate the understanding and appraisal of the review methods, as well as the detection of modifications to methods and selective reporting in completed reviews. We describe the development of a reporting guideline, the Preferred Reporting Items for Systematic reviews and Meta-Analyses for Protocols 2015 (PRISMA-P 2015). PRISMA-P consists of a 17-item checklist intended to facilitate the preparation and reporting of a robust protocol for the systematic review. Funders and those commissioning reviews might consider mandating the use of the checklist to facilitate the submission of relevant protocol information in funding applications. Similarly, peer reviewers and editors can use the guidance to gauge the completeness and transparency of a systematic review protocol submitted for publication in a journal or other medium. Background and using data from primary research, since planning Systematic reviews are the reference standard for syn- provides an opportunity for the review team to antici- thesizing evidence in health care because of their meth- pate potential problems. When clearly reported proto- odological rigor. They are used to support the cols are made available, they enable readers to identify development of clinical practice guidelines and inform deviations from planned methods in completed reviews clinical decision-making.
    [Show full text]
  • Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015 Statement
    Moher, D., Shamseer, L., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., Shekelle, P., Stewart, L. A., & PRISMA-P Group (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Systematic Reviews, 4, [1]. https://doi.org/10.1186/2046-4053-4-1 Publisher's PDF, also known as Version of record License (if available): CC BY Link to published version (if available): 10.1186/2046-4053-4-1 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via BioMed Central at https://systematicreviewsjournal.biomedcentral.com/articles/10.1186/2046-4053-4-1. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/red/research-policy/pure/user-guides/ebr-terms/ Moher et al. Systematic Reviews 2015, 4:1 http://www.systematicreviewsjournal.com/content/4/1/1 RESEARCH Open Access Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement David Moher1*, Larissa Shamseer1, Mike Clarke2, Davina Ghersi3, Alessandro Liberatiˆ, Mark Petticrew4, Paul Shekelle5, Lesley A Stewart6 and PRISMA-P Group Abstract Systematic reviews should build on a protocol that describes the rationale, hypothesis, and planned methods of the review; few reviews report whether a protocol exists. Detailed, well-described protocols can facilitate the understanding and appraisal of the review methods, as well as the detection of modifications to methods and selective reporting in completed reviews.
    [Show full text]
  • PRISMA-P Group (2015)
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Explore Bristol Research Shamseer, L., Moher, D., Clarke, M., Ghersi, D., Liberati, A., Petticrew, M., ... PRISMA-P Group (2015). Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ, 349, [g7647]. DOI: 10.1136/bmj.g7647 Publisher's PDF, also known as Version of record License (if available): CC BY-NC Link to published version (if available): 10.1136/bmj.g7647 Link to publication record in Explore Bristol Research PDF-document This is the final published version of the article (version of record). It first appeared online via BMJ at http://www.bmj.com/content/349/bmj.g7647. Please refer to any applicable terms of use of the publisher. University of Bristol - Explore Bristol Research General rights This document is made available in accordance with publisher policies. Please cite only the published version using the reference above. Full terms of use are available: http://www.bristol.ac.uk/pure/about/ebr-terms.html BMJ 2014;349:g7647 doi: 10.1136/bmj.g7647 (Published 2 January 2015) Page 1 of 25 Research Methods & Reporting RESEARCH METHODS & REPORTING Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation 1 1 2 3 4 Larissa Shamseer , David Moher , Mike Clarke , Davina Ghersi , Alessandro Liberati (deceased) , 5 6 7 Mark Petticrew , Paul Shekelle , Lesley A Stewart , the PRISMA-P Group 1Ottawa Hospital Research
    [Show full text]
  • Designing Efficient Systematic Reviews Using Economical Allocation, Creation and Synthesis of Medical Evidence
    CHILDREN AND FAMILIES The RAND Corporation is a nonprofit institution that helps improve policy and EDUCATION AND THE ARTS decisionmaking through research and analysis. ENERGY AND ENVIRONMENT HEALTH AND HEALTH CARE This electronic document was made available from www.rand.org as a public service INFRASTRUCTURE AND of the RAND Corporation. TRANSPORTATION INTERNATIONAL AFFAIRS LAW AND BUSINESS Skip all front matter: Jump to Page 16 NATIONAL SECURITY POPULATION AND AGING PUBLIC SAFETY Support RAND SCIENCE AND TECHNOLOGY Browse Reports & Bookstore TERRORISM AND Make a charitable contribution HOMELAND SECURITY For More Information Visit RAND at www.rand.org Explore the Pardee RAND Graduate School View document details Limited Electronic Distribution Rights This document and trademark(s) contained herein are protected by law as indicated in a notice appearing later in this work. This electronic representation of RAND intellectual property is provided for non- commercial use only. Unauthorized posting of RAND electronic documents to a non-RAND website is prohibited. RAND electronic documents are protected under copyright law. Permission is required from RAND to reproduce, or reuse in another form, any of our research documents for commercial use. For information on reprint and linking permissions, please see RAND Permissions. This product is part of the Pardee RAND Graduate School (PRGS) dissertation series. PRGS dissertations are produced by graduate fellows of the Pardee RAND Graduate School, the world’s leading producer of Ph.D.’s in policy
    [Show full text]
  • Academia and Clinic
    Annals of Internal Medicine Academia and Clinic Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement David Moher, PhD; Alessandro Liberati, MD, DrPH; Jennifer Tetzlaff, BSc; Douglas G. Altman, DSc; and the PRISMA Group* Editor’s Note: In order to encourage dissemination of the changing the name from QUOROM to PRISMA was the PRISMA Statement, this article is freely accessible on the An- desire to encompass both systematic reviews and meta- nals of Internal Medicine Web site (www.annals.org) and analyses. We have adopted the definitions used by the Co- will be also published in PLOS Medicine, BMJ, Journal of chrane Collaboration (9). A systematic review is a review of Clinical Epidemiology, and Open Medicine. The authors a clearly formulated question that uses systematic and ex- jointly hold the copyright of this article. For details on further plicit methods to identify, select, and critically appraise use, see the PRISMA Web site (www.prisma-statement.org). relevant research, and to collect and analyze data from the studies that are included in the review. Statistical methods ystematic reviews and meta-analyses have become in- (meta-analysis) may or may not be used to analyze and creasingly important in health care. Clinicians read S summarize the results of the included studies. Meta- them to keep up to date with their field (1, 2), and they are analysis refers to the use of statistical techniques in a sys- often used as a starting point for developing clinical prac- tematic review to integrate the results of included studies. tice guidelines. Granting agencies may require a systematic review to ensure there is justification for further research (3), and some health care journals are moving in this di- DEVELOPING THE PRISMA STATEMENT rection (4).
    [Show full text]
  • Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) 2015: Elaboration and Explanation OPEN ACCESS
    BMJ 2015;349:g7647 doi: 10.1136/bmj.g7647 (Published 2 January 2015) Page 1 of 25 Research Methods & Reporting BMJ: first published as 10.1136/bmj.g7647 on 2 January 2015. Downloaded from RESEARCH METHODS & REPORTING Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation OPEN ACCESS 1 1 2 3 4 Larissa Shamseer , David Moher , Mike Clarke , Davina Ghersi , Alessandro Liberati (deceased) , 5 6 7 Mark Petticrew , Paul Shekelle , Lesley A Stewart , the PRISMA-P Group 1Ottawa Hospital Research Institute and University of Ottawa, Canada; 2Queen’s University Belfast, Ireland; 3National Health and Medical Research Council, Australia; 4University of Modena, Italy; 5London School of Hygiene and Tropical Medicine, UK; 6Southern California Evidence-based Practice Center, USA; 7Centre for Reviews and Dissemination, University of York, UK Dedication: The PRISMA-P 2015 initiative is dedicated to our colleague encouraged to make use of PRISMA-P when drafting and appraising Alessandro Liberati (1954–2012), who passed away while PRISMA-P review protocols. 2015 was under development and whose contributions to this work were http://www.bmj.com/ invaluable. Introduction Abstract Systematic reviews hold a unique place in healthcare. They help Protocols of systematic reviews and meta-analyses allow for planning form the basis for developing practice guidelines and they and documentation of review methods, act as a guard against arbitrary provide information on gaps in knowledge, thus informing future decision making during review conduct, enable readers to assess for research efforts. This information is relevant to stakeholders the presence of selective reporting against completed reviews, and, across the health system.
    [Show full text]